Upstream Bio UPB
NASDAQ UPB
$6.01 -0.07 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Upstream Bio (UPB) EBT Margin Growth (1y) (2024 - 2026)

Analysis

Upstream Bio (UPB) EBT Margin Growth (1y) (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -153.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -571.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 553.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 4,709.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1,076.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1,911.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -392.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 29,565.00
10 Upstream Bio 327.95 Mn 327.95 Mn -3.29 Mn -87,702.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -87,702.00
Mar 31, 2026 132,690.00
Dec 31, 2025 -289,897.00
Sep 30, 2025 -230,426.00
Jun 30, 2025 -81,410.00
Mar 31, 2025 -323,423.00
Dec 31, 2024 -61,836.00
Sep 30, 2024 -136,856.00